Developer docs
API playgroundTry for free, no card

Search company profiles

Ichor Life Sciences

Full company profile

uuid00089yo

Namestring
Ichor Life Sciences
Legal namestring
Ichor Life Sciences, Inc.
Company typeenum
Private
Founded yearint
2013
Descriptiontext

Ichor Life Sciences is a privately held, US-based contract research organization (CRO) and venture studio founded in 2013 and headquartered in Syracuse, New York. The company provides preclinical research services to biotechnology and pharmaceutical clients through two main service divisions: Ichor Discovery Services (protein expression and purification across bacteria, yeast, insect, and mammalian systems; structural biology including X-ray crystallography; biophysical assays such as SPR, BLI, CD, nanoDSF, ITC, and NMR) and Ichor Pharmacology Services (drug discovery, cell-based assays, flow cytometry, histology, PK/PD, toxicology, and in vivo disease models spanning oncology, NASH, ophthalmology, geriatrics, cardiovascular, wound healing, and diet-induced obesity). In November 2023 the company added a third division, Ichor Clinical Trial Services, covering protocol design through close-out support, and in January 2024 extended this division internationally to Australia, Europe, and the UK through partnerships with Alithia Life Sciences and Afortiori Development. Ichor operates an AAALAC-accredited vivarium at its LaFayette, New York facility with in-house IACUC oversight and additional lab space at Clarkson University's Peyton Hall Biotechnology Incubator in Potsdam, NY.

The company derives the majority of its revenue from customized, project-based preclinical contract research engagements priced via quote, with services typically spanning multi-year contracts. A second revenue stream operates as a venture studio: Ichor launches and funds portfolio companies developing longevity- and aging-related therapeutics, including Lysoclear (enzyme therapy for macular degeneration and Stargardt's disease, launched 2014), Auctus Biologics (orally bioavailable 'ribobody' antibody mimetic scaffold, launched 2018), Lento Bio (anti-glycation small molecules for presbyopia, founded 2022 with Ichor as lead investor), MitoChem Therapeutics (mitochondrial dysfunction therapeutics, $1.5M Ichor investment 2022), and Cypris Therapeutics (therapeutically resistant cancers, launched 2024). Proprietary technology assets include the RPtag protein binding scaffold (23kD, orally bioavailable, derived from extremophile ribose-binding protein) and a custom SPR sensor for capturing protein complexes directly from cell lysate. Since 2013 the company has raised over $30 million in venture capital across its portfolio of companies under founder and CEO Dr. Kelsey Moody, PhD, MBA, and Chief Science Officer Dr. Aaron Wolfe, PhD.

Short descriptiontext

Ichor Life Sciences is a US-based preclinical and clinical contract research organization headquartered in Syracuse, NY, providing protein expression, structural biology, biophysical assays, in vivo pharmacology, toxicology, and clinical trial services to biotechnology and pharmaceutical companies, with an additional venture studio arm funding longevity and aging-related therapeutic companies.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLafayette, United States
HQ citystring
Lafayette
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
preclinical CRO services, contract research organization, drug discovery services, preclinical pharmacology services, protein expression services
Industry4 codes
PRIMARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)
SECONDARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAGAAAC
Toxicology & Safety Assessment CROs (GLP)
SECONDARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Contract Research Organization (Preclinical CRO Services)
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Contract Research Services
TypeProfessional Services
Description

Ichor generates revenue through providing preclinical contract research services including protein expression, structural biology, biophysical assays, cell-based assays, in vivo pharmacology studies, toxicology studies, PK/PD services, and clinical trial management. Services are offered as customized project-based engagements with biotechnology and pharmaceutical companies.

ichorlifesciences.com
2Strategic Investments
TypeLicensing Royalties
Description

Ichor makes strategic investments in portfolio companies (Lento Bio, MitoChem Therapeutics, Lysoclear, Auctus Biologics, Cypris Therapeutics) focused on longevity and aging-related therapeutics, demonstrating venture studio model.

ichorlifesciences.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
Pricing details1 tier
1Custom project-based pricing
ModelOtherBilling cadenceMulti-year contract
Notes

All services are quoted on a per-project basis based on client requirements, study complexity, and scope of work.

ichorlifesciences.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Ichor Life Sciences is a full-service preclinical and clinical contract research organization (CRO) providing end-to-end drug discovery and development services. Its offering spans protein expression and purification, structural biology, biophysical assays, cell-based assays, in vivo disease models, PK/PD studies, toxicology, and clinical trial management. The company operates a venture studio model, launching and investing in portfolio companies (Lysoclear, Lento Bio, MitoChem Therapeutics, Auctus Biologics, Cypris Therapeutics) focused on longevity and aging-related therapeutics.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Most projects start within 4 weeks of contract execution
+1 more record
Product overview1 text field

Ichor Life Sciences is a full-service preclinical contract research organization (CRO) providing end-to-end services from discovery through clinical trials. The company operates through two main service divisions: Ichor Discovery Services (protein manufacturing, structural biology, biophysics, and assay development) and Ichor Pharmacology Services (in vitro testing, histology, PK/PD, toxicology, and in vivo efficacy studies). A third division, Ichor Clinical Trial Services, extends capabilities into clinical stages. The company also maintains a portfolio of venture companies including Lysoclear (enzyme therapy for eye disease), Lento Bio (anti-glycation drugs), MitoChem Therapeutics (mitochondrial dysfunction), Auctus Biologics (ribobody platform), and Cypris Therapeutics (resistant disease treatments). Services span oncology, metabolic disease, musculoskeletal disease, ophthalmology, and geriatrics therapeutic areas.

Product and service1 record
1Ichor Discovery Services
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-01-24
Description

Strategic partnership with Australian CRO Alithia Life Sciences as part of Ichor Clinical's global expansion to Australia, providing clinical trial services with geographic expertise.

Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-01-24
Description

Partnership with Ireland/UK-based CRO Afortiori Development for clinical trial services as part of Ichor Clinical's expansion to Europe and UK markets.

3Clarity Clinical Research
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-11-14
Description

Lisa Sonneborn, now President of Ichor Clinical Trial Services, previously founded and served as CEO of Clarity Clinical Research, which was acquired by the world's largest site management organization in 2021. This experience informs Ichor's clinical trial service offerings.

ichorlifesciences.com
4SUNY-Upstate Medical University
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-09-08
Description

Collaboration with SUNY-Upstate Medical University on research article 'Coevolution of the Ess1-CTD axis in polar fungi suggests a role for phase separation in cold tolerance' published in Science Advances.

ichorlifesciences.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-07-20
Description

Dr. Kelsey Moody (CEO) and Dr. Aaron Wolfe (CSO) appointed to Lento Bio's board of directors and scientific advisory board respectively, bringing expertise in ophthalmology drug development and aging biology to support the company's therapeutic programs.

Recent move14 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global leader in preclinical CRO services including in vivo pharmacology, toxicology, and discovery research. Directly competes with Ichor's preclinical offerings but at vastly greater scale and broader therapeutic coverage.

TypeBroad incumbent
Description

One of the largest preclinical CROs globally, offering discovery, biology, DMPK, and toxicology services. Overlaps heavily with Ichor's protein expression, biophysical assays, and in vivo pharmacology capabilities.

TypeDirect peer
Description

Preclinical CRO and research models provider serving pharma and biotech with toxicology, safety assessment, and discovery services. Closely comparable in scale and therapeutic focus to Ichor's preclinical division.

TypeDirect peer
Description

Integrated drug discovery and development CRO offering structural biology, in vitro/in vivo pharmacology, and clinical services. Comparable end-to-end preclinical-to-clinical service model to Ichor.

TypeDirect peer
Description

China/UK/US-based preclinical CRO providing protein expression, structural biology, in vitro/in vivo pharmacology, DMPK, and toxicology services. Directly overlaps with Ichor's discovery and pharmacology service lines.

TypeDirect peer
Description

Preclinical CRO specializing in oncology and immuno-oncology in vivo models, with translational platforms. Overlaps with Ichor's oncology/immuno-oncology in vivo disease models and pharmacology services.

TypeDirect peer
Description

Mid-sized preclinical CRO offering biochemical and cell-based assays, biophysics, and protein production services. Closely comparable in scale and service mix to Ichor's discovery division.

TypeBroad incumbent
Description

Division of Eurofins Scientific providing drug discovery and preclinical services including biophysics, in vitro pharmacology, and ADME. Overlaps with Ichor's assay development and pharmacology service lines.

TypeDirect peer
Description

Australian boutique CRO partnered with Ichor Clinical for clinical trial services. Provides clinical CRO capabilities comparable to Ichor's clinical trial services division in a regional geography.

TypeDirect peer
Description

Mid-sized CRO offering preclinical discovery and clinical trial management. Comparable integrated service model to Ichor's preclinical-plus-clinical positioning.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment4 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Ichor Life Sciences

Contract Research Organization (Preclinical CRO Services)ichorlifesciences.com

Ichor Life Sciences is a US-based preclinical and clinical contract research organization headquartered in Syracuse, NY, providing protein expression, structural biology, biophysical assays, in vivo pharmacology, toxicology, and clinical trial services to biotechnology and pharmaceutical companies, with an additional venture studio arm funding longevity and aging-related therapeutic companies.

What Ichor Life Sciences does

Ichor Life Sciences is a privately held, US-based contract research organization (CRO) and venture studio founded in 2013 and headquartered in Syracuse, New York. The company provides preclinical research services to biotechnology and pharmaceutical clients through two main service divisions: Ichor Discovery Services (protein expression and purification across bacteria, yeast, insect, and mammalian systems; structural biology including X-ray crystallography; biophysical assays such as SPR, BLI, CD, nanoDSF, ITC, and NMR) and Ichor Pharmacology Services (drug discovery, cell-based assays, flow cytometry, histology, PK/PD, toxicology, and in vivo disease models spanning oncology, NASH, ophthalmology, geriatrics, cardiovascular, wound healing, and diet-induced obesity). In November 2023 the company added a third division, Ichor Clinical Trial Services, covering protocol design through close-out support, and in January 2024 extended this division internationally to Australia, Europe, and the UK through partnerships with Alithia Life Sciences and Afortiori Development. Ichor operates an AAALAC-accredited vivarium at its LaFayette, New York facility with in-house IACUC oversight and additional lab space at Clarkson University's Peyton Hall Biotechnology Incubator in Potsdam, NY.

The company derives the majority of its revenue from customized, project-based preclinical contract research engagements priced via quote, with services typically spanning multi-year contracts. A second revenue stream operates as a venture studio: Ichor launches and funds portfolio companies developing longevity- and aging-related therapeutics, including Lysoclear (enzyme therapy for macular degeneration and Stargardt's disease, launched 2014), Auctus Biologics (orally bioavailable 'ribobody' antibody mimetic scaffold, launched 2018), Lento Bio (anti-glycation small molecules for presbyopia, founded 2022 with Ichor as lead investor), MitoChem Therapeutics (mitochondrial dysfunction therapeutics, $1.5M Ichor investment 2022), and Cypris Therapeutics (therapeutically resistant cancers, launched 2024). Proprietary technology assets include the RPtag protein binding scaffold (23kD, orally bioavailable, derived from extremophile ribose-binding protein) and a custom SPR sensor for capturing protein complexes directly from cell lysate. Since 2013 the company has raised over $30 million in venture capital across its portfolio of companies under founder and CEO Dr. Kelsey Moody, PhD, MBA, and Chief Science Officer Dr. Aaron Wolfe, PhD.

Ichor Life Sciences firmographics

Firmographics
Name
Ichor Life Sciences
Legal name
Ichor Life Sciences, Inc.
Website
https://ichorlifesciences.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
11–50 employees
Short description
Ichor Life Sciences is a US-based preclinical and clinical contract research organization headquartered in Syracuse, NY, providing protein expression, structural biology, biophysical assays, in vivo pharmacology, toxicology, and clinical trial services to biotechnology and pharmaceutical companies, with an additional venture studio arm funding longevity and aging-related therapeutic companies.
Ownership category
akta.pro rank

Ichor Life Sciences industry classification

Industry
Product category
Contract Research Organization (Preclinical CRO Services)
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)
SECONDARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAGAAAC
Toxicology & Safety Assessment CROs (GLP)
SECONDARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)

Keywords

  • Preclinical CRO services
  • Contract research organization
  • Drug discovery services
  • Preclinical pharmacology services
  • Protein expression services

Where Ichor Life Sciences is headquartered

Location

Headquarters

HQ city
Lafayette
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Ichor Life Sciences business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. Contract Research Services: Ichor generates revenue through providing preclinical contract research services including protein expression, structural biology, biophysical assays, cell-based assays, in vivo pharmacology studies, toxicology studies, PK/PD services, and clinical trial management. Services are offered as customized project-based engagements with biotechnology and pharmaceutical companies.
  2. Strategic Investments: Ichor makes strategic investments in portfolio companies (Lento Bio, MitoChem Therapeutics, Lysoclear, Auctus Biologics, Cypris Therapeutics) focused on longevity and aging-related therapeutics, demonstrating venture studio model.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom project-based pricing

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Ichor Life Sciences product offering

Product offering

Core offering

Ichor Life Sciences is a full-service preclinical and clinical contract research organization (CRO) providing end-to-end drug discovery and development services. Its offering spans protein expression and purification, structural biology, biophysical assays, cell-based assays, in vivo disease models, PK/PD studies, toxicology, and clinical trial management. The company operates a venture studio model, launching and investing in portfolio companies (Lysoclear, Lento Bio, MitoChem Therapeutics, Auctus Biologics, Cypris Therapeutics) focused on longevity and aging-related therapeutics.

Product overview

Ichor Life Sciences is a full-service preclinical contract research organization (CRO) providing end-to-end services from discovery through clinical trials. The company operates through two main service divisions: Ichor Discovery Services (protein manufacturing, structural biology, biophysics, and assay development) and Ichor Pharmacology Services (in vitro testing, histology, PK/PD, toxicology, and in vivo efficacy studies). A third division, Ichor Clinical Trial Services, extends capabilities into clinical stages. The company also maintains a portfolio of venture companies including Lysoclear (enzyme therapy for eye disease), Lento Bio (anti-glycation drugs), MitoChem Therapeutics (mitochondrial dysfunction), Auctus Biologics (ribobody platform), and Cypris Therapeutics (resistant disease treatments). Services span oncology, metabolic disease, musculoskeletal disease, ophthalmology, and geriatrics therapeutic areas.

Differentiator

Problem solved

Functional benefit

Products and services

  • Ichor Discovery Services

Quantifiable outcome

  • Most projects start within 4 weeks of contract execution
  • +1 more outcomes

Companies that use Ichor Life Sciences

Customer profile

Segments3 records

Ideal customer profiles3 records

Ichor Life Sciences technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Ichor Life Sciences partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered minor and core.

  • Alithia Life SciencesminorChannel Partner/ Reseller/ Distributor · 24 January 2024Strategic partnership with Australian CRO Alithia Life Sciences as part of Ichor Clinical's global expansion to Australia, providing clinical trial services with geographic expertise.
  • Afortiori DevelopmentminorChannel Partner/ Reseller/ Distributor · 24 January 2024Partnership with Ireland/UK-based CRO Afortiori Development for clinical trial services as part of Ichor Clinical's expansion to Europe and UK markets.
  • Clarity Clinical ResearchminorStrategic or Co-development Partner · 14 November 2023Lisa Sonneborn, now President of Ichor Clinical Trial Services, previously founded and served as CEO of Clarity Clinical Research, which was acquired by the world's largest site management organization in 2021. This experience informs Ichor's clinical trial service offerings.
  • SUNY-Upstate Medical UniversityminorStrategic or Co-development Partner · 8 September 2022Collaboration with SUNY-Upstate Medical University on research article 'Coevolution of the Ess1-CTD axis in polar fungi suggests a role for phase separation in cold tolerance' published in Science Advances.
  • Lento BiocoreStrategic or Co-development Partner · 20 July 2022Dr. Kelsey Moody (CEO) and Dr. Aaron Wolfe (CSO) appointed to Lento Bio's board of directors and scientific advisory board respectively, bringing expertise in ophthalmology drug development and aging biology to support the company's therapeutic programs.

Scale indicators5 records

Recent moves14 records

Expansion highlights5 records

Ichor Life Sciences competitors and assessment

Company assessment

Broad incumbents

  • Charles River Laboratories: Global leader in preclinical CRO services including in vivo pharmacology, toxicology, and discovery research. Directly competes with Ichor's preclinical offerings but at vastly greater scale and broader therapeutic coverage.
  • WuXi AppTec: One of the largest preclinical CROs globally, offering discovery, biology, DMPK, and toxicology services. Overlaps heavily with Ichor's protein expression, biophysical assays, and in vivo pharmacology capabilities.
  • Eurofins Discovery: Division of Eurofins Scientific providing drug discovery and preclinical services including biophysics, in vitro pharmacology, and ADME. Overlaps with Ichor's assay development and pharmacology service lines.

Direct peers

  • Inotiv: Preclinical CRO and research models provider serving pharma and biotech with toxicology, safety assessment, and discovery services. Closely comparable in scale and therapeutic focus to Ichor's preclinical division.
  • Evotec: Integrated drug discovery and development CRO offering structural biology, in vitro/in vivo pharmacology, and clinical services. Comparable end-to-end preclinical-to-clinical service model to Ichor.
  • Pharmaron: China/UK/US-based preclinical CRO providing protein expression, structural biology, in vitro/in vivo pharmacology, DMPK, and toxicology services. Directly overlaps with Ichor's discovery and pharmacology service lines.
  • Crown Bioscience: Preclinical CRO specializing in oncology and immuno-oncology in vivo models, with translational platforms. Overlaps with Ichor's oncology/immuno-oncology in vivo disease models and pharmacology services.
  • Reaction Biology: Mid-sized preclinical CRO offering biochemical and cell-based assays, biophysics, and protein production services. Closely comparable in scale and service mix to Ichor's discovery division.
  • Alithia Life Sciences: Australian boutique CRO partnered with Ichor Clinical for clinical trial services. Provides clinical CRO capabilities comparable to Ichor's clinical trial services division in a regional geography.
  • Sundia MediTech (now Sundia Clinical Services): Mid-sized CRO offering preclinical discovery and clinical trial management. Comparable integrated service model to Ichor's preclinical-plus-clinical positioning.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Ichor Life Sciences social profiles

Digital presence

Ichor Life Sciences compliance and trust

Trust signal

Compliance1 record

Ichor Life Sciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Ichor Life Sciences leadership team

Management profile

Number of profiles

Profiles4 records

Ichor Life Sciences funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Ichor Life Sciences M&A and investment

M&A and investment

M&A

Investments4 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ichor Life Sciences

What does Ichor Life Sciences do?

Ichor Life Sciences is a full-service preclinical and clinical contract research organization (CRO) providing end-to-end drug discovery and development services. Its offering spans protein expression and purification, structural biology, biophysical assays, cell-based assays, in vivo disease models, PK/PD studies, toxicology, and clinical trial management. The company operates a venture studio model, launching and investing in portfolio companies (Lysoclear, Lento Bio, MitoChem Therapeutics, Auctus Biologics, Cypris Therapeutics) focused on longevity and aging-related therapeutics.

Is Ichor Life Sciences a public or private company?

Ichor Life Sciences is a private company. It is classified as venture growth investor backed and is currently operating.

When was Ichor Life Sciences founded?

Ichor Life Sciences was founded in 2013. It employs 11 to 50 people.

Where is Ichor Life Sciences based?

Ichor Life Sciences is headquartered in Lafayette, United States, in the North America region.

How does Ichor Life Sciences make money?

Two revenue lines are on record. Contract Research Services are the primary driver. The others are strategic Investments.

Who are Ichor Life Sciences's main competitors?

Broad incumbents on record are Charles River Laboratories, WuXi AppTec and Eurofins Discovery. Direct peers are Inotiv, Evotec, Pharmaron, Crown Bioscience, Reaction Biology, Alithia Life Sciences and Sundia MediTech (now Sundia Clinical Services).

Does Ichor Life Sciences have an API?

No public API is recorded for Ichor Life Sciences.

What industry is Ichor Life Sciences in?

Ichor Life Sciences's product category is Contract Research Organization (Preclinical CRO Services). Its primary akta.pro industry code is HLAGAAAB, Preclinical CROs (Discovery/Pharmacology/DMPK), with a secondary code of HLAGAAAA, Clinical CROs (Phase I–IV). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MorningstarCypris Therapeutics Launches as Newest Ichor Life Sciences Portfolio Company, Secures Over $500k in Pre-Seed FundingCypris Therapeutics launched as a new Ichor Life Sciences portfolio company, securing over $500,000 in pre-seed funding led by Ichor. The company will incubate at Ichor's facilities and use its synthetic chemistry technology to develop novel cancer treatments, including for brain and pancreatic cancers.Business Wire BlogCypris Therapeutics Launches as Newest Ichor Life Sciences Portfolio Company, Secures Over $500k in Pre-Seed FundingCypris Therapeutics launched as a new Ichor Life Sciences portfolio company, securing over $500,000 in pre-seed funding led by Ichor. The drug discovery firm's synthetic chemistry technology targets therapeutically resistant cancers, including brain and pancreatic cancers. The company will incubate at Ichor's facilities and seek additional funding and partnerships.Business Wire BlogCypris Therapeutics Launches as Newest Ichor Life Sciences Portfolio Company, Secures Over $500k in Pre-Seed FundingCypris Therapeutics launched as a new Ichor Life Sciences portfolio company, securing over $500,000 in pre-seed funding. The drug discovery firm uses synthetic chemistry to develop novel chemistries for therapeutically resistant cancers, including brain and pancreatic cancers. It will incubate at Ichor's facilities and seek additional funding and partnerships.BioSpaceCypris Therapeutics Launches as Newest Ichor Life Sciences Portfolio Company, Secures Over $500k in Pre-Seed FundingCypris Therapeutics has launched as a new portfolio company of Ichor Life Sciences, securing over $500,000 in pre-seed funding to develop novel chemistries for therapeutically resistant diseases like brain and pancreatic cancers. The startup will incubate at Ichor's facilities, utilizing its equipment and expertise to iterate on natural molecule-based small moieties.MitochemincICHOR Life Sciences Invests $1.5 Million — MitoChem Therapeutics, Inc.Ichor Life Sciences announced a $1.5 million investment in MitoChem Therapeutics to advance research on treatments for ocular aging diseases. The collaboration aims to develop a small molecule pharmaceutical eyedrop targeting mitochondrial dysfunction, with MitoChem opening a satellite lab at Clarkson University to support the work.